| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.038 | 0.5 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.5 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.046 | 0.5 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |